AREDS2 Under Scrutiny: Advocating Unified Regulations

Area of Science:

• Ophthalmology
• Nutritional Science
• Pharmacology

Background:

• Age-related macular degeneration (AMD) is a primary cause of vision loss in elderly populations.
• Dietary supplements following the AREDS2 formulation are recognized for slowing intermediate AMD progression.

Purpose of the Study:

• To systematically compare the ingredient composition of over-the-counter (OTC) AMD supplements with the AREDS2 formula.
• To quantify deviations in nutrient content from the established AREDS2 reference values.

Main Methods:

• Market analysis of AMD supplements available in Germany.
• Comparison of declared ingredients and dosages against AREDS2 study reference values.

Main Results:

• Most analyzed supplements showed significant deviations from the AREDS2 formulation.
• Average concentrations were lower: Vitamin C by 52.3%, Vitamin E by 61.2%, Zinc by 40.1%.
• Few products precisely matched the AREDS2 composition and dosage.

Conclusions:

• Substantial discrepancies exist in commercially available AREDS2-based AMD supplements.
• Standardized labeling and regulatory guidelines are needed for better comparability.
• Enhanced standardization would support evidence-based clinical use of AMD supplements.